1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties

被引:67
作者
Kim, In-Hae [1 ]
Tsai, Hsing-Ju [1 ]
Nishi, Kosuke [1 ]
Kasagami, Takeo [1 ]
Morisseau, Christophe [1 ]
Hammock, Bruce D. [1 ]
机构
[1] Univ Calif Davis, Ctr Canc, Dept Entomol, Davis, CA 95616 USA
关键词
D O I
10.1021/jm070705c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Soluble epoxide hydrolase (sEH) is a therapeutic target for treating hypertension and inflammation. 1,3-Disubstituted ureas functionalized with an ether group are potent sEH inhibitors. However, their relatively low metabolic stability leads to poor pharmacokinetic properties. To improve their bioavailability, we investigated the effect of incorporating various polar groups on the ether function on the inhibition potencies, physical properties, in vitro metabolic stability, and pharmacokinetic properties. The structure- activity relationship studies showed that a hydrophobic linker between the urea group and the ether function is necessary to keep their potency. In addition, urea-ether inhibitors having a polar group such as diethylene glycol or morpholine significantly improved their physical properties and metabolic stability without any loss of inhibitory potency. Furthermore, improved pharmacokinetic properties in murine and canine models were obtained with the resulting inhibitors. These findings will facilitate the usage of sEH inhibitors in animal models of hypertension and inflammation.
引用
收藏
页码:5217 / 5226
页数:10
相关论文
共 35 条
[1]   CDNA CLONING AND EXPRESSION OF A SOLUBLE EPOXIDE HYDROLASE FROM HUMAN LIVER [J].
BEETHAM, JK ;
TIAN, TG ;
HAMMOCK, BD .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 305 (01) :197-201
[2]   New role for epoxyeicosatrienoic acids as anti-inflammatory mediators [J].
Campbell, WB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (04) :125-127
[3]  
Capdevila JH, 2000, J LIPID RES, V41, P163
[4]   A new class of lipid mediators: cytochrome P450 arachidonate metabolites [J].
Carroll, MA ;
McGiff, JC .
THORAX, 2000, 55 :S13-S16
[5]   Cytochrome P4502C is an EDHF synthase in coronary arteries [J].
Fisslthaler, B ;
Popp, R ;
Kiss, L ;
Potente, M ;
Harder, DR ;
Fleming, I ;
Busse, R .
NATURE, 1999, 401 (6752) :493-497
[6]   Epoxide hydrolases: biochemistry and molecular biology [J].
Fretland, AJ ;
Omiecinski, CJ .
CHEMICO-BIOLOGICAL INTERACTIONS, 2000, 129 (1-2) :41-59
[7]  
GRANT DF, 1993, J BIOL CHEM, V268, P17628
[8]  
HAMMOCK BD, 1977, COMPREHENSIVE TOXICO, P283
[9]   Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors [J].
Hwang, Sung Hee ;
Morisseau, Christophe ;
Do, Zung ;
Hammock, Bruce D. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (22) :5773-5777
[10]   An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension [J].
Imig, JD ;
Zhao, XY ;
Zaharis, CZ ;
Olearczyk, JJ ;
Pollock, DM ;
Newman, JW ;
Kim, IH ;
Watanabe, T ;
Hammock, BD .
HYPERTENSION, 2005, 46 (04) :975-981